WORTZMAN MARILYN E 4
4 · Transcept Pharmaceuticals Inc · Filed Aug 25, 2011
Insider Transaction Report
Form 4
WORTZMAN MARILYN E
VP, Finance
Transactions
- Award
Employee Stock Option (right to buy)
2011-08-24+77,500→ 77,500 totalExercise: $2.68Exp: 2021-08-24→ Common Stock (77,500 underlying)
Footnotes (1)
- [F1]Fifty percent of the option vests upon approval by the U.S. Food and Drug Administration ("FDA") of Intermezzo and the remaining 50% vest on the first anniversary of any such approval; provided, in each case, such approval occurs no later than August 24, 2013. These options automatically expire should the Board of Directors decide to cease development of Intermezzo or if Intermezzo approval is not received on or prior to August 24, 2013.